The Low Risk Transcatheter Aortic Valve Replacement Trials —An Analysis
TRANSCATHETER AORTIC valve replacement (TAVR) has revolutionized the treatment of aortic stenosis (AS). Surgical intervention to treat AS (before TAVR) mandated general anesthesia, invasive vascular monitoring, sternotomy, cardiopulmonary bypass, and several days of postoperative hospital stay. With balloon aortic valvuloplasty being the only palliative percutaneous option, surgery was the only interventional treatment for AS as recent as 15 years ago. Initial approval for TAVR use began with Comite Europee Marking in 2007 and United States Food and Drug Administration (FDA) approval in 2011, and the procedure has been rapidly adopted worldwide.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Daniel Cormican, Stephen McHugh, Michael Boisen, Daniel Winter, Chak-yu So, Pedro A. Villablanca, Harish Ramakrishna Tags: Expert Review Source Type: research
More News: Anesthesia | Anesthesiology | Aortic Stenosis | Cardiology | Food and Drug Administration (FDA) | Heart | Heart Valve Surgery | Hospitals | Palliative | USA Health